PD-L1 immunohistochemistry (IHC) assay is now FDA-approved as a companion diagnostic biomarker to select patients most likely to benefit from ICI treatment for multiple cancer types, such as non-small cell lung cancer(NSCLC), metastatic TNBC, and melanoma (5). This evidence concerns the gene CD274 and cancer.